TY -JOR T1-与睡眠有关的呼吸障碍和肺动脉高压JF-欧洲呼吸杂志2020/01/01 ur-http：//www.qdcxjkg.com/content/early/2020/07/30/13993003.022258-2020.Abstract N2-与睡眠相关的呼吸障碍包括阻塞性呼吸暂停，中央呼吸暂停，中央呼吸暂停，和睡眠不足。。这些夜间事件有可能在睡眠期间和醒来状态增加肺动脉压。“纯”阻塞性睡眠呼吸暂停综合征导致肺动脉压的少量增加，尚未证明其临床影响。相比之下，在肥胖症不足综合征或重叠综合征（COPD与阻塞性睡眠呼吸暂停的关联）中，夜间呼吸事件有助于肺动脉高压的发展，这通常很严重。在后一种情况下，与睡眠相关的呼吸障碍的治疗对于改善肺部血流动力学至关重要。患有肺动脉高压或慢性血栓栓塞性肺动脉高压的患者有患与睡眠相关的呼吸障碍的风险。可以观察到阻塞性和中央呼吸暂停，以及在睡眠期间通风灌注不匹配的恶化。在这样的患者人群中，应该强烈怀疑与睡眠有关的呼吸障碍，但是睡眠研究的确切指示和记录的类型仍有待指定。肺动脉高压或慢性血栓栓塞性肺动脉高压症患者中阻塞性睡眠呼吸暂停综合征的诊断应鼓励以持续的气道阳性压力治疗。孤立的夜间低氧血症的存在也应引发长期氧疗法的开始。 These treatments are likely to avoid worsening of pulmonary hypertension. However, it is prudent not to treat central apnoea and Cheynes-Stokes respiration with adaptive servo-ventilation in patients with chronic right heart failure because of a potential risk of serious adverse effects from such treatment.In this review we will consider the current knowledge of the consequences of sleep-related breathing disorders on pulmonary haemodynamics in patients with and without chronic respiratory disease (group 3 of the clinical classification of pulmonary hypertension) and the effect of treatments of respiratory events during sleep on pulmonary hypertension. The prevalence, consequences and therapeutic options of sleep-related breathing disorders in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension will also be discussed (groups 1 and 4 of the clinical classification of pulmonary hypertension, respectively).FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Momen has nothing to disclose.Conflict of interest: Yochai Adir has received personal fees for lecturing and/or consulting from Actelion, Boehringer Ingelheim, Teva, Bayer, GlaxoSmithKline, Roche, Novartis, AstraZeneca, Kamada and UT Pharmaceuticals, and research grants from Actelion, Bayer, Boehringer Ingelheim and GlaxoSmithKlineConflict of interest: Dr. Humbert reports personal fees from Actelion, grants and personal fees from Bayer, grants and personal fees from GSK, personal fees from Merck, from United Therapeutics, outside the submitted work.Conflict of interest: Ari Chaouat has received personal fees for lecturing and/or consulting from Actelion, Boehringer Ingelheim, Novartis, MSD, Chiesi and research grants from Actelion and GlaxoSmithKline ER -